The struggling retail pharmacy chain entered an agreement to be purchased by private equity firm Sycamore Partners, which could end its nearly 100-year run as a public company.

CBO Abbas Kazimi will replace longtime CEO Jeb Keiper as part of a planned leadership transition at the unorthodox drug ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

The Johns Hopkins surgeon highlighted rapid growth at the agency, but pledged key staff will have “all the resources they ...

Questioned by senators at a Thursday hearing, President Trump's FDA nominee said he would reevaluate which scientific topics ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Interrupted access to the data has already led to worse outcomes and could undermine faith in the U.S. healthcare system, ...

Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, the FDA cleared for ...

A District Court judge issued a nationwide preliminary injunction against the administration’s plan to cap so-called indirect ...

The Greenwood lab features an expanded temperature range of -70°C to +60°C while maintaining the ability to conduct ...

Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma.